Scienza e Tecnologia
SkylineDx inks collaboration agreement with Imperial College London and UCSD on diagnostic test Kawasaki Disease
"Professor Michael Levin and his team in the Department of Infectious Disease have an international reputation for research on pediatric infectious diseases. We are very impressed with the dedication and research done by them to care for these children", continues Dharminder Chahal , CEO SkylineDx. "It is a big step for our company as we are applying our know-how outside of oncology for the first time and our teams are making significant progress in the assay development efforts".
SkylineDx is a biotechnology company, focused on research & development of molecular diagnostics in oncology and inflammatory diseases. The company is headquartered in Rotterdam ( the Netherlands ) and complemented with a field medical and scientific affairs team in the US and a CAP/CLIA certified laboratory in San Diego ( California ). SkylineDx uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility, assisting healthcare professionals in accurately determining the type or status of disease or predict a patient's response to treatment. Based on test results, healthcare professionals can tailor the treatment approach to the individual patient. To learn more, please visit www.skylinedx.com.
1. Link to this press release on website SkylineDx (click here)
2. Wright et al. Diagnosis of Kawasaki Disease Using a Minimal Whole-Blood Gene Expression Signature. JAMA Pediatrics 2018;172(10):e182293 (click here)